UNITY registrational topline: efgartigimod in Sjogren's disease
argenx expects to report results from its Registrational (UNITY) study of Efgartigimod (Vyvgart) for Sjogren's disease in the second half of 2027 (no exact date yet). Registrational (UNITY) is a study designed to support approval.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- argenx SE ARGX
- Drug
- Efgartigimod (Vyvgart)
- For
- Sjogren's disease
- Stage
- Registrational (UNITY) · a study designed to support approval
- When
- H2 2027 · the company gave a window, not a day; the calendar never invents one
- Source note
- H1 2026 results PR: 'Topline results from registrational UNITY study (Sjogren's disease) expected in second half of 2027.'
- Checked
- Checked by a person when it was added
- Source: argenx.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- ARGX headlines on this site
Adimanebart (ARGX-119) registrational study start in congenital myasthenic syndromes, expected during 2026 (no exact date yet). A company milestone for argenx (adimanebart (ARGX-119) for congenital myasthenic syndromes): a step in the program rather than a decision or a data readout.
More details
- Entry
- Adimanebart (ARGX-119) registrational study start in congenital myasthenic syndromes · Company milestone
- Drug
- adimanebart (ARGX-119)
- For
- congenital myasthenic syndromes
- Stage
- Registrational · a study designed to support approval
- When
- 2026 · the company gave a window, not a day
- Source note
- Q2 2026 PR (Jul 23, 2026) guides 2026 start; the Q1 2026 PR had said 'CMS registrational study on track to start in third quarter of 2026'. Using the less precise, more recent guidance.
- Checked
- Checked by a person when it was added
- Verify it
- Source: argenx.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- ARGX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
ARGX-121 (anti-IgA) Phase 2 start in IgA nephropathy, expected during 2026 (no exact date yet). A company milestone for argenx (ARGX-121 for IgA nephropathy): a step in the program rather than a decision or a data readout.
More details
- Entry
- ARGX-121 (anti-IgA) Phase 2 start in IgA nephropathy · Company milestone
- Drug
- ARGX-121
- For
- IgA nephropathy
- Stage
- Phase 2 · the stage that tests whether the drug actually works
- When
- 2026 · the company gave a window, not a day
- Source note
- argenx H1 2026 results (Jul 23, 2026) reiterated 2026 Phase 2 start for ARGX-121 in IgAN.
- Checked
- Checked by a person when it was added
- Verify it
- Source: argenx.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- ARGX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
ARGX-118 and ARGX-125 to enter Phase 1 in 2026, expected during 2026 (no exact date yet). A company milestone for argenx (ARGX-118 / ARGX-125 for undisclosed): a step in the program rather than a decision or a data readout.
More details
- Entry
- ARGX-118 and ARGX-125 to enter Phase 1 in 2026 · Company milestone
- Drug
- ARGX-118 / ARGX-125
- For
- undisclosed
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- 2026 · the company gave a window, not a day
- Source note
- argenx H1 2026 results (Jul 23, 2026): two new first-in-class molecules on track for Phase 1 entry in 2026 (TSP-101 Phase 1 already ongoing).
- Checked
- Checked by a person when it was added
- Verify it
- Source: argenx.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- ARGX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
argenx expects to report results from its Registrational (EMPASSION) study of Empasiprubart (ARGX-117) for Multifocal motor neuropathy (MMN) in Q4 2026 (Oct–Dec) (no exact date yet). Registrational (EMPASSION) is a study designed to support approval.
More details
- Entry
- EMPASSION registrational topline: empasiprubart in multifocal motor neuropathy · Clinical trial results (readout / topline data)
- Drug
- Empasiprubart (ARGX-117)
- For
- Multifocal motor neuropathy (MMN)
- Stage
- Registrational (EMPASSION) · a study designed to support approval
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- H1 2026 results PR: 'Topline results from registrational EMPASSION study (MMN) expected in fourth quarter of 2026.'
- Checked
- Checked by a person when it was added
- Verify it
- Source: argenx.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- ARGX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
ARGX-124 (next-gen FcRn) to complete Phase 1 evaluation by end of 2026, expected in Q4 2026 (Oct–Dec) (no exact date yet). A company milestone for argenx (ARGX-124 for FcRn (undisclosed autoimmune)): a step in the program rather than a decision or a data readout.
More details
- Entry
- ARGX-124 (next-gen FcRn) to complete Phase 1 evaluation by end of 2026 · Company milestone
- Drug
- ARGX-124
- For
- FcRn (undisclosed autoimmune)
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- argenx H1 2026 results PR (Jul 23, 2026) guides ARGX-124 Phase 1 completion by year-end 2026; ARGX-213 described as Phase 3 ready. Dated Q4 per 'by end of 2026'.
- Checked
- Checked by a person when it was added
- Verify it
- Source: argenx.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- ARGX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
argenx expects to report results from its Registrational (ADVANCE-NEXT) study of Efgartigimod (Vyvgart) for Primary immune thrombocytopenia in the first half of 2027 (no exact date yet). Registrational (ADVANCE-NEXT) is a study designed to support approval.
More details
- Entry
- ADVANCE-NEXT registrational topline: efgartigimod in primary ITP · Clinical trial results (readout / topline data)
- Drug
- Efgartigimod (Vyvgart)
- For
- Primary immune thrombocytopenia
- Stage
- Registrational (ADVANCE-NEXT) · a study designed to support approval
- When
- H1 2027 · the company gave a window, not a day
- Source note
- H1 2026 results PR: 'Topline results from registrational ADVANCE-NEXT study (primary ITP) expected in first half of 2027.'
- Checked
- Checked by a person when it was added
- Verify it
- Source: argenx.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- ARGX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page